Molecular Therapy

FIGURE 4

FROM:

A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer

Eric J. Small, Michael A. Carducci, James M. Burke, Ron Rodriguez, Lawrence Fong, Lynn van Ummersen, D. C. Yu, Junko Aimi, Dale Ando, Peter Working, David Kirn and George Wilding

BACK TO ARTICLE

Figure 4.

Figure and tables index
Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Dose-related decreases in diastolic and systolic blood pressure after CG7870 dosing. The maximum percentage change in patient blood pressure from baseline to 8–12 hours after treatment is represented for each patient in gray bars (diastolic top panel; systolic, lower panel). The mean change for each dose group is represented by the black bar (absolute number for mean change shown). Bars directed upward (above the zero line) represent an increase in blood pressure, whereas a bar directed downward represents a decrease in blood pressure.

Figure and tables index
BACK TO ARTICLE